Conditioning therapy with N‐acetyl‐L‐cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26903
Abstract: Conditioning therapy is an essential procedure prior to hematopoietic stem cell transplant (HSCT), imposing a great impact on the outcomes of recipients. We performed a prospective randomized controlled trial to assess the outcome of HSCT… read more here.
Keywords: arm; decitabine; myeloid malignancies; therapy ... See more keywords
The role of ASXL1 in hematopoiesis and myeloid malignancies
Sign Up to like & getrecommendations! Published in 2019 at "Cellular and Molecular Life Sciences"
DOI: 10.1007/s00018-019-03084-7
Abstract: Recent high-throughput genome-wide sequencing studies have identified recurrent somatic mutations in myeloid neoplasms. An epigenetic regulator, Additional sex combs-like 1 (ASXL1), is one of the most frequently mutated genes in all subtypes of myeloid malignancies.… read more here.
Keywords: role; myeloid malignancies; asxl1 mutations; hematopoiesis ... See more keywords
Neutrophilic Dermatoses Associated with Myeloid Malignancies
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Clinical Dermatology"
DOI: 10.1007/s40257-018-00418-2
Abstract: Neutrophilic dermatoses (ND) are a group of conditions characterized by an aseptic accumulation of polymorphonuclear leukocytes in the skin. Occurrence of ND in association with myeloid malignancies, mainly myelodysplastic syndrome and myelogenous acute leukemia, is… read more here.
Keywords: dermatology; dermatoses associated; neutrophilic dermatoses; associated myeloid ... See more keywords
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.07.005
Abstract: The combination of 5-azacytidine (AZA) with donor lymphocyte infusions (DLIs) can induce remissions in patients with relapsed myeloid malignancies after allo-HCT. As decitabine (DAC) is known to be effective also in AML/MDS with leukocytosis, we… read more here.
Keywords: combination; allo hct; lymphocyte infusions; donor lymphocyte ... See more keywords
An epitranscriptomic vulnerability in myeloid malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Nature Medicine"
DOI: 10.1038/nm.4435
Abstract: A recent study finds that the N6-methyladenosine (m6A) modifier METTL3 regulates proliferation and differentiation in myeloid cells and acute myeloid leukemia (AML). read more here.
Keywords: medicine; vulnerability myeloid; myeloid malignancies; epitranscriptomic vulnerability ... See more keywords
Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
Sign Up to like & getrecommendations! Published in 2018 at "Blood Cancer Journal"
DOI: 10.1038/s41408-018-0148-6
Abstract: Given the vast phenotypic and genetic heterogeneity of acute and chronic myeloid malignancies, hematologists have eagerly awaited the introduction of next-generation sequencing (NGS) into the routine diagnostic armamentarium to enable a more differentiated disease classification,… read more here.
Keywords: sequencing ngs; introduction next; myeloid malignancies; next generation ... See more keywords
TIM-3 pathway dysregulation and targeting in cancer
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2021.1865814
Abstract: ABSTRACT Introduction Dysfunction of the immune system is a hallmark of cancer. Through increased understanding of the complex interactions between immunity and cancer, immunotherapy has emerged as a treatment modality for different types of cancer.… read more here.
Keywords: pathway dysregulation; treatment; tim; cancer ... See more keywords
Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2073214
Abstract: ABSTRACT Background Relapse is the leading cause of death from myeloid malignancies after allogeneic hematopoietic stem cell transplantation (HSCT). Azacitidine has gained attention in recent years in the prophylaxis of relapsed refractory hematologic malignancies. This… read more here.
Keywords: stem cell; myeloid malignancies; cell transplantation; relapse ... See more keywords
1140. GATA2 Mutations Are Frequently Identified Among Patients With Myeloid Malignancies Who Develop Invasive Aspergillosis
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.973
Abstract: Abstract Background Patients with myeloid malignancies are at risk of invasive aspergillosis (IA), a cause of significant morbidity and mortality. Identification of patients at higher risk for IA may help optimize prophylactic or preemptive treatment… read more here.
Keywords: gata2 mutations; risk; among patients; invasive aspergillosis ... See more keywords
Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications
Sign Up to like & getrecommendations! Published in 2021 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000675
Abstract: Purpose of review Clinical and experimental studies have uncovered relevant clinical implications of clonal hematopoiesis. However, the true magnitude of this process, clonal dynamics over time and mechanisms of progression into overt malignancy remain to… read more here.
Keywords: myeloid malignancies; hematopoiesis; clonal dynamics; clinical implications ... See more keywords
Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies.
Sign Up to like & getrecommendations! Published in 2022 at "Current opinion in hematology"
DOI: 10.1097/moh.0000000000000691
Abstract: PURPOSE OF REVIEW The antitumor activity of macrophages is regulated by a balance of prophagocytic and antiphagocytic signals. Cluster of differentiation 47 (CD47), the dominant macrophage immune checkpoint ('do not eat me' signal), interacts with… read more here.
Keywords: regulatory protein; myeloid malignancies; myeloid; protein alpha ... See more keywords